ÂÜÀòÂÒÂ×

Peter Smith is an accomplished executive in the biotechnology sector with a strong focus on cancer treatment and drug discovery. Currently serving as Executive Chair, Executive Director, and Non-Executive Director at Race Oncology since July 2023, Peter plays a key role in advancing the company's mission in cancer care through its lead asset, bisantrene. Peter has also been a Non-Executive Director at MycRx since February 2018, contributing to Myc drug discovery programs. As the Founder and CEO of Amala Therapeutics, established in August 2015, Peter leads efforts to preserve muscle in diseased states. Additionally, Peter has held various leadership roles, including Non-Executive Director at Hula Therapeutics and former CEO positions at Myrio Tx, Avipep Pty Ltd, Alchemia Limited, and Amrad Corporation. Educationally, Peter holds a Ph.D. in Biochemistry and a B.A. in Natural Sciences from the University of Cambridge.